

30.11.2017

HAEMATO AG - IFRS Results Q3 2017

HAEMATO AG is a listed pharmaceutical company with focus on the growth markets of high-end specialty pharmaceuticals in the indication groups of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market has started. HAEMATO AG expects that first products will be launched in the coming year, which has already created the basis for further growth and additional income.

HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 72.5 million and an operating result (EBIT) of EUR 2.45 million in the third quarter of 2017. Sales thus increased by 2.4% in the comparable prior-year period. Within the first nine months of 2017, total revenue amounts to 211.3 million euros and EBIT to 5.64 million euros. The Management Board forecasts consolidated revenue of more than 280 million euros for the entire 2017 financial year.

About HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The emphasis of business activities lies on the growth markets of high-priced specialty pharmaceuticals. The focus lies on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG:

Subscribed capital: EUR 21,980,000

Listed share class: bearer ordinary shares

ISIN: DE0006190705 • WKN: 619070 • Stock symbol: HAE